SAN DIEGO , Feb. 15, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces the appointment of Michael Terry to the newly
SAN DIEGO , Feb. 21, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it will release financial results for the
Revenues increased more than five-fold in 2016 and nearly six-fold in the fourth quarter of 2016Company to host conference call at 4:30 p.m. Eastern time today
SAN DIEGO , March 8, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that President and CEO Michael W.
Catalyst Pharmaceuticals to make Biocept's Target Selector™ test available to LEMS patients in Phase III Firdapse® trial to screen for cancer every six months for up to two years, at no cost to patients
SAN DIEGO , March 15, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that David Moskowitz , Vice President of Strategy
SAN DIEGO , March 28, 2017 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the outcomes of cancer patients, today announced that it has entered into securities purchase agreements with certain
SAN DIEGO , March 31, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that President and CEO Michael W.
NCI-designated cancer institute with leading molecular pathology lab obtains rights to utilize and commercially offer Biocept's Target Selector™ liquid biopsy services throughout the state of OregonKnight Diagnostic Laboratories to work with Biocept to co-develop highly sensitive, multiplexed assay panels leveraging OHSU's next generation sequencing (NGS) expertise
